

REVIEW ARTICLE

Usefulness of knockout mice to clarify the role of the opioid system in chronic pain

Correspondence Rafael Maldonado and David Cabañero, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), C/ Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: rafael.maldonado@upf.edu; david.cabanero@upf.edu

Received 10 May 2017; **Revised** 13 October 2017; **Accepted** 17 October 2017

Rafael Maldonado^{1,2} , Josep Eladi Baños^{1,2}  and David Cabañero¹ 

¹Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain, and ²IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Several lines of knockout mice deficient in the genes encoding each component of the endogenous opioid system have been used for decades to clarify the specific role of the different opioid receptors and peptide precursors in many physiopathological conditions. The use of these genetically modified mice has improved our knowledge of the specific involvement of each endogenous opioid component in nociceptive transmission during acute and chronic pain conditions. The present review summarizes the recent advances obtained using these genetic tools in understanding the role of the opioid system in the pathophysiological mechanisms underlying chronic pain. Behavioural data obtained in these chronic pain models are discussed considering the peculiarities of the behavioural phenotype of each line of knockout mice. These studies have identified the crucial role of specific components of the opioid system in different manifestations of chronic pain and have also opened new possible therapeutic approaches, such as the development of opioid compounds simultaneously targeting several opioid receptors. However, several questions still remain open and require further experimental effort to be clarified. The novel genetic tools now available to manipulate specific neuronal populations and precise genome editing in mice will facilitate in a near future the elucidation of the role of each component of the endogenous opioid system in chronic pain.

LINKED ARTICLES

This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit <http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc>

Abbreviations

Cas9, CRISPR-associated protein 9; CFA, complete Freund's adjuvant; CNO, clozapine N-oxide; CRISPR, clustered regulatory interspaced short palindromic repeats; DOP, δ -opioid receptor; DREADD, designed receptor exclusively activated by designed drugs; KOP, κ -opioid receptor; MOP, μ -opioid receptor; N/OFQ, nociceptin/orphanin FQ peptide; NOP, nociceptin/orphanin receptor; *Oprd1*, gene coding for δ -opioid receptor; *Oprk1*, gene coding for κ -opioid receptor; *Oprl1*, gene coding for nociceptin/orphanin receptor; *Oprm1*, gene coding for μ -opioid receptor; *Pdyn*, prodynorphin gene; *Penk*, proenkephalin gene; PKA, cAMP-dependent protein kinase; *Pomc*, proopiomelanocortin gene; PSNL, partial sciatic nerve ligation

Introduction

The endogenous opioid system is composed of three opioid receptors, μ -opioid receptor (MOP), δ -opioid receptor (DOP) and κ -opioid receptor (KOP), and their endogenous ligands derived from three precursors, proopiomelanocortin, proenkephalin and prodynorphin. Opioid precursor genes proopiomelanocortin gene (*Pomc*), proenkephalin gene (*Penk*) and prodynorphin gene (*Pdyn*), respectively, were identified in the early 1980s, whereas the genes encoding for MOP (*Oprm1*), DOP (*Oprd1*) and KOP (*Oprk1*) were identified a decade later (Kieffer and Evans,

2009). Opioid peptides derived from *Penk*, mainly [Met] and [Leu]enkephalin, are preferential ligands of DOP, although also show affinity for MOP. The opioid peptide derived from *Pomc*, β -endorphin, shows affinity for both MOP and DOP, whereas opioid peptides derived from *Pdyn*, dynorphins and neodynorphins, are preferential agonists of KOP (Kosterlitz, 1985).

The endogenous opioid system plays a crucial role in the control of nociceptive responses at peripheral, spinal and supra-spinal level (Figure 1). In physiological conditions, the neural process of encoding noxious stimuli starts with stimulation of A δ and C nociceptors innervating peripheral




Figure 1

Schematic view of ascending and descending pain pathways, opioid locations and main effects in physiological conditions. A, A primary afferent fibres; ACC, anterior cingulate cortex; C, C primary afferent fibres; Enk, enkephalins; β -end, β -endorphin; Dyn, dynorphins; Hipp, hippocampus; mPFC, medial prefrontal cortex; NAcc, nucleus accumbens; NMDAR, N-methyl-D-aspartate receptor; OFF, off cells; ON, on cells; PAG, periaqueductal gray; PCx, parietal cortex; RVM, rostral ventromedial medulla; S1 and S2, somatosensory cortex 1 and 2; TH, thalamus.

tissues. These fibres synapse with projection neurons in the spinal cord dorsal horn, which send information to supra-spinal areas. At the peripheral level, opioid peptides released by immune cells during inflammation locally inhibit pain transmission (Rittner *et al.*, 2008). At the spinal level, stimulation of presynaptic opioid receptors from nociceptors inhibits the release of neurotransmitters. Spinal cord dorsal horn projection neurons convey inputs from peripheral and supra-spinal projections, and post-synaptic opioid receptors inhibit their activity. However, activation of the endogenous opioid system at spinal level can also have pro-nociceptive effects in certain conditions, generally attributed to spinal dynorphins (Povdin *et al.*, 2016).

Dorsal horn neurons project their axons to the thalamus and limbic areas of the brain, and thalamic neurons connect to the somatosensory cortex S1 and S2, allowing temporal and spatial discrimination of the noxious stimuli. Activation of limbic areas results in affective and motivational consequences of pain, which, in case of sustained activation, can evolve to pain-related anxiety, depression and cognitive impairment. Opioid receptors and peptides are expressed in these brain areas, which include the amygdala, nucleus accumbens and medial prefrontal and anterior cingulate cortices. At the same time, emotional and cognitive factors are known to modulate pain perception (Bushnell *et al.*, 2013). While a negative emotional state can increase the unpleasantness of pain regardless of the perceived intensity, a decreased attention to the painful area can diminish the intensity of the pain sensation. This different pain modulation by cognitive and affective aspects is probably due to the different circuitry involved, being the attentional alterations associated with activity in the insula and the parietal and somatosensory cortices (Bushnell *et al.*, 2013) and descending modulation by negative affect associated with activation of the periaqueductal gray (PAG) and the anterior cingulate and medial prefrontal cortices. Interestingly, these areas are also under control of the endogenous opioid system (Henriksen and Willoch, 2008; Lutz and Kieffer, 2013).

The PAG receives inputs from the amygdala and cortical areas and sends projections to the rostral ventromedial medulla (RVM). In the RVM, On and Off neurons have axons that reach the dorsal horn of the spinal cord to facilitate (On cells) or inhibit (Off cells) nociceptive transmission (Ossipov *et al.*, 2010). Opioid receptor activation in the PAG inhibits the cells that keep inhibited Off cells in the RVM, whereas On cells are the only cells directly inhibited by opioids in the RVM. The endogenous opioid system also modulates the activity of noradrenergic neurons in the locus coeruleus, which also inhibit synaptic transmission in the spinal cord. Thus, at this level, opioids inhibit nociceptive transmission both by direct inhibition of On cells and disinhibition of Off cells and by increasing noradrenergic activity in the spinal cord (see Nadal *et al.*, 2013). The opioid system also participates in the control of several other physiological functions including emotional and rewarding responses, cognition, locomotion, feeding behaviour, body temperature, endocrine, cardiovascular, respiratory and gastrointestinal functions (Terenius, 2000; Polunina and Bryun, 2013; Bodnar, 2017).

Activation of nociceptive pathways during nociceptive and acute inflammatory pain avoids further damage to the

organism and has an adaptive function. However, in some circumstances, inflammatory pain persists and becomes chronic, or chronic pain can be a result of abnormal functioning of the nervous system (pathological pain). Pathological maladaptive pain is not a symptom of a disorder and can be associated with damage of the nervous system (neuropathic pain) or to conditions in which there is no neuronal damage or inflammation (dysfunctional pain) (Woolf, 2010). The modification of behavioural and physiological responses by the opioid system could influence the manifestations of acute and chronic pain.

Another receptor, the **nociceptin/orphanin receptor** (NOP), and its endogenous ligand, the **nociceptin/orphanin FQ** peptide (N/OFQ), were also proposed to integrate the endogenous opioid system (Meunier, 1997). This receptor and endogenous peptide have been involved in nociceptive transmission, although its activation counteracts most of the classical opioid effects (Schröder *et al.*, 2014; Kiguchi *et al.*, 2016). Indeed, N/OFQ produces hyperalgesia in rodents when administered by intracerebroventricular route and analgesia when intrathecally administered, not suppressed by **naloxone** (Witkin *et al.*, 2014). The actions of the N/OFQ system are not restricted to nociceptive pathways. Indeed, NOP activation induces hypolocomotion, ataxia and loss of righting reflex, impairs spatial learning, increases feeding behaviour and regulates release of pituitary hormones (Schröder *et al.*, 2014; Toll *et al.*, 2016).

Different lines of genetically modified mice have been generated with mutations targeting specific components of the opioid system. These genetic models have provided invaluable tools to study the physiological role of the different opioid receptors and peptide precursors (Gavériaux-Ruff, 2013). Constitutive deletion of a targeted gene by homologous recombination in embryonic stem cells has allowed the generation of many lines of conventional knockout mice for nearly three decades. The phenotypic characterization of these knockout mice has provided important advances in the knowledge of several physiological and pathological processes, including chronic pain. Genetic approaches targeting specific brain regions or neuronal populations are now providing additional advances in the knowledge of the specific mechanisms underlying chronic pain. Thus, the Cre-lox P system has been used to generate conditional deletions of opioid system components in specific tissues. The generation of conditional Cre-lox P knockouts requires the introduction of the sites for Cre recombinase (lox P sites) in direct orientation, flanking the gene of interest. These 'floxed' mice integrating the two loxP sites will delete the gene of interest upon delivery or expression of the Cre recombinase in the cells in which recombination is required (Morozov *et al.*, 2003).

Knockout mice have been extensively used to evaluate the involvement of the opioid system in the control of nociceptive responses. Several reviews have summarised the advances provided by these genetic tools in pain control (Dierich and Kieffer, 2004; Nadal *et al.*, 2013). However, these reviews are mainly focused on the role of endogenous opioid components in acute pain and the antinociceptive responses induced by different opioid compounds. While moderate to severe acute pain can be efficiently treated with opioids, opioid treatment of chronic pain has many deleterious

consequences for the patients. Blunted efficacy of opioids, tolerance, hyperalgesia and addiction undermine the efficiency of these treatments (Trang *et al.*, 2015). Understanding how the opioid system works during chronic inflammatory and neuropathic pain will be essential to optimize current treatments or to develop strategies for effective pain management. In the present review, we have summarized the recent advances obtained using knockout mice in understanding the role of the different components of the opioid system in the pathophysiological mechanisms underlying chronic pain. The models used to evaluate and mimic inflammatory and neuropathic pain conditions in the opioid knockouts are listed in Table 1. Behavioural data obtained in these models of chronic pain should be interpreted with careful consideration of the peculiarities of the behavioural phenotype of each line of knockout mice.

Studies on knockout mice deficient in MOP, DOP and their endogenous ligands

MOP constitutive knockout mice have been obtained by disruption of exon 1 (Sora *et al.*, 1997; Tian *et al.*, 1997; Schuller *et al.*, 1999), exon 2 (Matthes *et al.*, 1996), exon 2 and 3 (Loh *et al.*, 1998; van Rijn and Whistler, 2009) or exon 11 (Pan *et al.*, 2009) of the *Oprm1* gene in mice with C57BL/6 or mixed C57BL/6-129S background (Figure 2). Additionally, conditional knockout with MOP exon 2 and 3 deleted in **Na_v1.8** (Weibel *et al.*, 2013) and **TRPV1** positive neurons (Corder *et al.*, 2017) have also been published.

Due to the extended editing of the *Oprm1* gene (Pasternak and Pan, 2013), the different constructions of MOP knockouts resulted in the expression of different splice variants in the various strains generated. Exon 1 knockouts lack the canonical 7-transmembrane (7-TM) MOP and hence are not sensitive to **morphine**. However, they keep the genomic sequence coding for 6 transmembrane (6-TM) domains and were described to express 6-TM splice variants of the MOP (Schuller *et al.*, 1999; Lu *et al.*, 2015). This maintained their sensitivity to other opioids, including **heroin**, **6-acetylmorphine**, morphine-6-glucuronide or **fentanyl**, which still could act through the 6-TM MOP (Schuller *et al.*, 1999). However, exon 1 knockouts generated by other groups (Sora *et al.*, 1997) showed decreased G-protein activation after exposure to these opioids. Thus, it is unclear whether these other exon 1 knockouts still express the 6-TM MOP. Interestingly, exon 11 knockouts maintain the 7-TM forms of the MOP but cannot produce the 6-TM variants (Pan *et al.*, 2009). Hence, these mice were sensitive to morphine but not to morphine-6-glucuronide or fentanyl. Moreover, exon 11 knockouts failed to show morphine-induced hyperalgesia, developed less tolerance and did not display hyperlocomotion after repeated morphine administration (Marrone *et al.*, 2017), associating these negative consequences of opioid treatments with the 7-TM MOP splice variants. On the other hand, exon 2 or exon 2–3 knockouts are expected to lack both 6 and 7-TM variants (Pasternak and Pan, 2013) and showed loss of sensitivity to morphine and

fentanyl (Matthes *et al.*, 1996; Weibel *et al.*, 2013). Thus, it is important to take into account the specific genetic modifications, as they may result in different behavioural outcomes depending on the phenotype being tested.

Exon 1, 2 and 2–3 knockouts showed increased sensitivity to heat, hypolocomotion and a disruption of the analgesic effects of MOP agonists (Ide *et al.*, 2006, 2008; Pan *et al.*, 2009; Kögel *et al.*, 2011; Gavériaux-Ruff, 2013). Baseline mechanical sensitivity was generally unaltered when assessing light touch sensitivity with von Frey hairs, although nociceptive responses to stronger mechanical stimuli were increased (Fuchs *et al.*, 1999; Martin *et al.*, 2003). Indeed, abdominal contractions in response to colorectal distension were also increased in constitutive exon 2–3 knockouts, but not in conditional **Na_v1.8** knockouts, suggesting a role of central MOP controlling basal colon mechanosensation (Gavériaux-Ruff *et al.*, 2008).

A given cognitive or emotional trait in the rodent strains could also affect the phenotypes observed in the chronic pain models. In the case of the MOP knockouts, basal anxiolytic and anti-depressive phenotype restricted to males were reported using classical behavioural paradigms (Filliol *et al.*, 2000), in contrast to the increased anxiety in conflict and defensive conditions, aggressiveness and deficits in social behaviour independent of the gender of these mutants (Becker *et al.*, 2014). Other features that may indirectly affect chronic pain manifestations include cognitive impairment not associated with attentional deficits (Jamot *et al.*, 2003; Sanders *et al.*, 2005), increased haematopoiesis or sexual dysfunction (Tian *et al.*, 1997).

The literature exploring chronic pain in MOP knockouts have reported increased, no difference or decreased nociceptive behaviour depending on each specific study. Although this heterogeneity suggests a lack of reproducibility at first glance, a closer inspection of the results may give some interesting conclusions. Divergent results may indicate a complex role for MOP in the pathophysiology of chronic pain that could be explained by the multiplicity of MOP knockout models or also by methodological differences.

Partly conflicting results were obtained in different models of inflammatory pain. For instance, exon 1 knockout mice showed increased response in the late phase and no change in the early phase of the **formalin** test (Zhao *et al.*, 2003), whereas exon 2 knockouts showed increased reflex responses in the early phase and no change in the late phase (Martin *et al.*, 2003). An effect of the different genetic deletions and certain methodological differences could have favoured these divergent results. While the first study injected 2% formalin in the hindpaw and measured the number of flinches, the second one injected 5% formalin and measured the time licking, shaking or biting the paw. The significance of an increased response in each of the phases may have different interpretations (Table 1), although both studies showed antinociceptive effects of MOP.

Exon 1 MOP knockout mice showed divergent results in other models of inflammatory pain. Initial studies showed decreased number of writhings in the acetic acid model of abdominal pain (Sora *et al.*, 1999), increased responsiveness to chemical stimulation in the formalin test (Qiu *et al.*, 2000) and decreased heat sensitivity after complete Freund's adjuvant (CFA) (Qiu *et al.*, 2000), suggesting different MOP

Table 1

Models used to evaluate pain manifestations (A) and to mimic inflammatory and neuropathic pain conditions (B) in opioid knockout mice

		Name of the model	Principle	Response recorded
(A) Models used to evaluate pain manifestations	Mechanical sensitivity	von Frey	A battery of filaments of increasing diameter/weight is applied to the plantar surface of the hind paw	Paw withdrawal threshold (weight)
		von Frey – dynamic Plantar aesthesiometer	Automated device gradually applies a single probe against the plantar surface of the hind paw	Paw withdrawal threshold (weight)
		Tail pressure	Increasing pressure applied to the tail with an analgesia meter	Pressure applied when tail is withdrawn (weight)
	Heat sensitivity	Plantar test	Radiant heat source applied against the plantar surface of the hind paw	Paw withdrawal latency (time)
		Hot tail immersion	Tail immersion in a heated water bath	Tail withdrawal latency (time)
		Tail-flick	Radiant heat source applied to the tail	Tail withdrawal latency (time)
		Hot plate	Mice walking on a heated surface	Paw withdrawal latency/latency to jump/time licking, lifting, shaking the paws
	Cold sensitivity	Cold plate	Mice walking on a cold surface	Difference in paw elevations ipsilateral to the injury versus contralateral
		Acetone drop	Application of acetone drop to plantar surface of the paw	Time licking/lifting/shaking the paw
	Visceral sensitivity	Visceromotor response to colorectal distension	Colorectal distension with a balloon catheter	Electromyographic recording of abdominal contractions
	Memory	Object recognition memory	Exposure to novel and familiar objects in a V-shaped maze	Score based on time exploring new object versus time exploring familiar object indicates degree of recognition memory
	Anxiety	Elevated plus maze	Placement on a plus-shaped elevated maze with two open and two closed arms communicating at the intersection	Number of crossings to open/closed arms, and time spent in open/closed arms
		Name of the model	Principle	What models?
(B) Models mimicking inflammatory or neuropathic pain conditions	Inflammatory pain	Formalin	Formalin solution injected s.c. into dorsal or plantar paw. Two response phases: -early (0–5 min), direct activation nociceptors -late (15–60 min), tonic inflammation and central sensitization. Time licking, shaking or biting the injected paw, or number of flinches are recorded.	Acute inflammatory pain
		CFA	CFA injected s.c. into the plantar surface of a hindpaw. Punctate mechanical, heat and cold sensitivity develops.	Chronic inflammatory pain
		Acetic acid writhing	Injection of acetic acid solution i.p. (dissolved in distilled water). Number of writhes are counted.	Visceral pain
		Dextran sodium sulphate-induced colitis	Colitis induced by adding 3% dextran sulphate sodium to the drinking water for 5 days. The visceromotor response of abdominal muscles is recorded.	Visceral pain
		Zymosan A	Zymosan A s.c. injected into the plantar side of hind paw. Punctate mechanical and heat sensitivity develop.	Acute inflammatory pain
		Monoiodoacetate (MIA)	Intraarticular injection of MIA in the knee joint. Punctate mechanical sensitivity, anxiety-like behaviour and memory impairment are induced.	Osteoarthritis pain

continues

Table 1

(Continued)

	Name of the model	Principle	What models?
	Cartilage defects in knee joints	Osteochondral defects made with a Kirshner wire in femoral trochlear groove of a knee joint	Cartilage defects
Neuropathic pain	Sciatic nerve cuffing	Implantation of a cuff around the main branch of the sciatic nerve. Punctate mechanical sensitivity is induced.	Peripheral neuropathic pain
	Chronic constriction injury	3–4 loose ligatures around sciatic nerve. Punctate mechanical and heat sensitivity develop.	Peripheral neuropathic pain
	Streptozocin-induced diabetic neuropathy	Animals treated with streptozotocin (200 mg/kg i.p.). Punctate mechanical and heat sensitivity develop.	Diabetic neuropathy
	Partial sciatic nerve ligation (PSNL; Seltzer model)	Tight ligation of cranial 1/3 of sciatic nerve. Punctate mechanical, heat and cold sensitivity are induced.	Peripheral neuropathic pain
	Spared nerve injury	Transection of tibial and common peroneal nerves. Punctate mechanical sensitivity is induced.	Peripheral neuropathic pain
	Post-herpetic neuralgia	s.c. inoculation of varicella zoster virus on the scarified shin. Punctate mechanical sensitivity develops.	Post-herpetic allodynia




Figure 2

Use of opioid receptor knockout mice in chronic pain models. Cold, cold sensitivity; Heat, heat sensitivity; KO, knockout; Mechano, mechanical sensitivity; MIA, monoiodoacetate model; TCA, tricyclic antidepressants. *Only results found on affective/cognitive behaviour in opioid receptor knockouts subjected to chronic pain models. Black boxes: C57BL/6 background; black-brown boxes: C57BL/6-129S.

modulation depending on the pain model. However, later studies in exon 1 knockouts did not detect changes in heat sensitivity after CFA (Gendron *et al.*, 2007) or in heat and mechanical sensitivity after carrageenan-induced inflammation (Mansikka *et al.*, 2004). Another source of conflicting data was the antinociception mediated by DOP. Enhanced antinociceptive effects of the DOP agonists **DPDPE** ([D-Pen2,5]-enkephalin) and **deltorphin-II** were reported

in exon 1 knockouts in C57BL/6-129/S background (Qiu *et al.*, 2000), whereas reduced deltorphin-II and **SNC80** antinociception was shown in a similar CFA model using C57BL/6 mice with exon 1 knockouts (Gendron *et al.*, 2007). In this case, different strain sensitivity to the DOP agonists may have favoured this conflicting data, since previous studies already showed threefold reduced morphine sensitivity in C57BL/6 versus 129/S mice. Importantly, the reported

differences in nociception between these strains could have contributed to the heterogeneity of the results in these opioid knockouts (Mogil and Wilson, 1997). Given the divergent results obtained in exon 1 knockouts, we need to know if the different exon 1 strains express similar splice variants. While some groups (Schuller *et al.*, 1999) characterized the expression of 6-TM MOP in these mice, this was not examined in exon 1 knockouts generated by other groups (Sora *et al.*, 1997; Tian *et al.*, 1997). Further studies may help to clarify these apparently conflicting results and the specific participation of 6/7-TM splice variants in the chronic pain phenotypes.

Exon 11 knockouts (lacking 7-TM but preserving 6-TM variants) showed no change or marginal increases in mechanical sensitivity in the CFA model of inflammatory pain (Wieskopf *et al.*, 2014) and unaltered mechanical sensitivity after spared nerve injury. However, these data were obtained with a dynamic plantar aesthesiometer (Table 1) and may not be directly comparable to mechanosensitivity data obtained with the other strains, generally evaluated using the von Frey filaments.

Using a similar model of inflammatory pain, exon 2 knockouts showed increased mechanical hypersensitivity after CFA (Walwyn *et al.*, 2016). However, another study showed unchanged responses to heat and mechanical stimuli after CFA using exon 2 knockouts in mice with a similar C57BL/6 background (Gavériaux-Ruff *et al.*, 2008). Methodological differences may have contributed to these divergent data. The former study (Walwyn *et al.*, 2016) estimated the 50% paw withdrawal threshold, whereas the latter (Gavériaux-Ruff *et al.*, 2008) used more restrictive conditions, considering the threshold as the thinnest filament eliciting 60% of positive responses. Similarly, mice lacking MOP in **Na_v1.8** primary afferent fibres did not show altered sensitivity to inflammatory somatic or visceral pain. However, MOP in these fibres participated in the analgesic effects of classical MOP agonists during chronic inflammation induced by CFA, but not in basal conditions (Weibel *et al.*, 2013; Reiss *et al.*, 2016). In the same line of results, the visceromotor response to colorectal distension after the induction of experimental colitis was similar in exon 2–3 knockouts and control mice. Hence, exon 2 or 2–3 knockouts showed no effect or antinociceptive effect of MOP in inflammatory pain conditions, depending on the specific study.

Neuropathic pain models also showed divergent data in studies conducted with exon 1 or exon 2/2–3 MOP knockouts. Exon 1 knockouts exhibited enhanced mechanical, but not heat or cold hypersensitivity after unilateral nerve injury on L5 (Mansikka *et al.*, 2004). Again, the interpretation of these results is difficult because the expression or absence of 6-TM MOP has not been characterized in these mice. Exon 2/2–3 knockouts showed no differences in mechanical sensitivity to von Frey hairs after cuffing the sciatic nerve (Bohren *et al.*, 2010), whereas decreased nocifensive behaviour to thermal stimulation was observed in a model of diabetic neuropathy (Kögel *et al.*, 2011). In the same direction, exon 2 knockouts showed attenuated sensitivity to cold after partial ligation of the sciatic nerve (PSNL) (Maldonado, 2016), suggesting pronociceptive effects of MOP. This view may be in agreement with a recent study using conditional MOP exon 2–3 knockouts in TRPV1-

positive neurons (Corder *et al.*, 2017). The study revealed absence of morphine tolerance and morphine-induced hyperalgesia in these mice, attributing a role to peripheral MOP in these detrimental consequences of opioid treatments (Corder *et al.*, 2017). Hence, according to the results obtained with exon 2/2–3 knockouts, this opioid receptor may play antinociceptive roles in certain conditions of chronic inflammatory pain, whereas the results obtained with neuropathic pain models suggest a maladaptive function of MOP in abnormal pain conditions. Thus, treatments with MOP agonists might be considered during chronic inflammatory pain, and these MOP agonists would act through peripheral sites. However, the application of MOP agonists during chronic neuropathic pain may be counterproductive.

Constitutive DOP knockouts were obtained by homologous recombination of *Oprd1* exon 1 (Filliol *et al.*, 2000) or 2 (Zhu *et al.*, 1999; van Rijn and Whistler, 2009) in mice with mixed C57BL/6–129S or complete C57BL/6 background, and new conditional models have been obtained by deletion of exon 2 in primary afferents expressing **Na_v1.8** channels (Gavériaux-Ruff *et al.*, 2011) or in **GABAergic** neurons of the forebrain (van Rijn and Whistler, 2009; Chu Sin Chung *et al.*, 2015). In these models, DOP appears to be critical in maintaining affective stability and cognitive performance. Indeed, mice constitutively lacking DOP showed anxious and depressive-like phenotype (Filliol *et al.*, 2000), and an impairment in learning and short-term memory (Le Merrer *et al.*, 2013). It could be expected that a basal phenotype characterized by negative affect would favour nociceptive sensitivity (Bushnell *et al.*, 2013). However, at least in baseline conditions, nociceptive thresholds to somatic thermal or mechanical stimuli were not modified (Filliol *et al.*, 2000; Martin *et al.*, 2003; Nadal *et al.*, 2006; Gavériaux-Ruff *et al.*, 2008). Interestingly, abdominal contractions in response to colorectal distension were increased, as in the MOP knockout animals, but this was not observed in conditional **Na_v1.8** knockouts, suggesting a role of central DOP on basal colon sensitivity.

The presence of DOP acquires more relevance in chronic pain conditions. Indeed, DOP knockouts developed increased thermal and mechanical sensitivity in models of chronic neuropathic (Nadal *et al.*, 2006) and inflammatory pain (Gavériaux-Ruff *et al.*, 2008), suggesting a protective role of DOP for the development of these chronic pain manifestations. This antinociceptive role of DOP was also observed in the late phase of the formalin test (Martin *et al.*, 2003) and in pharmacological experiments with constitutive DOP knockouts revealing a crucial role of this receptor for the anti-allodynic effects of tricyclic antidepressants and DOP agonists (Benbouzid *et al.*, 2008; Gavériaux-Ruff *et al.*, 2008; Gavériaux-Ruff, 2013). On the contrary, the abdominal response to colorectal distension after experimental colitis was similar in DOP knockout and wild-type mice (Reiss *et al.*, 2016).

Conditional knockouts have been used to correlate the nociceptive phenotypes with DOP deletion in specific nervous system regions. Thus, DOP ablation in primary afferent fibres expressing **Na_v1.8** revealed the involvement of these receptors in chronic pain (Gavériaux-Ruff *et al.*, 2011). Indeed, these conditional mutants showed unchanged heat

hyperalgesia but increased mechanical allodynia after CFA and enhanced mechanical and cold hypersensitivity after PSNL (Gaveriaux-Ruff *et al.*, 2011). As constitutive DOP knockouts showed increased sensitivity to heat and this increase was absent in the conditional lines, this suggests that central DOP control heat hypersensitivity in chronic pain conditions. Another conditional knockout line targeting DOP in forebrain GABAergic neurons (Dlx5/6) has been generated (Chu Sin Chung *et al.*, 2015). Surprisingly, these mice showed lower levels of anxiety, in contrast to the anxious characteristics of constitutive DOP knockouts (Filliol *et al.*, 2000). Although the consequences of this conditional DOP deletion in the development of chronic pain have not been yet investigated, it is not yet known if the heightened chronic pain sensitivity in constitutive DOP knockouts could be influenced by their inherent depressive and anxious phenotype. However, it seems clear that DOP have an overall protective function on nociceptive sensitivity during both chronic inflammatory and neuropathic pain conditions, partly mediated through their function on primary afferent neurons. While DOP from peripheral neurons control mechanical and cold sensitivity, DOP in central structures modulate heat hypernociception.

Knockout mice deficient in the precursors of the opioid peptides acting on MOP and DOP have also been generated (Figure 3). β -endorphin knockouts were obtained by a point mutation in exon 3 of the *Pomc* gene in a mixed C57BL/6-129S background, which resulted in a premature stop codon not affecting the expression of other *Pomc*-derived peptides (Rubinstein *et al.*, 1996). Baseline thermal and mechanical

nociceptive thresholds were unaltered (Gendron *et al.*, 2007; Petraschka *et al.*, 2007; Fell *et al.*, 2014; Walwyn *et al.*, 2016) or slightly increased (Mogil *et al.*, 2000; Trigo *et al.*, 2009). These mutants showed normal anxiety-like behaviour (Trigo *et al.*, 2009) and a reduced motivation for food (Hayward *et al.*, 2002). In addition, these mice lacked stress-induced analgesia and showed a delayed thermal hyperalgesia after forced swimming (Parikh *et al.*, 2011).

In chronic pain models, β -endorphin knockout mice showed normal nociceptive sensitization to thermal and mechanical stimuli in inflammatory (Gendron *et al.*, 2007; Walwyn *et al.*, 2016) and peripheral neuropathy models (Petraschka *et al.*, 2007; Niikura *et al.*, 2008a,b; Labuz *et al.*, 2016). However, these mice retained sensitivity to MOP agonists during neuropathic pain, whereas wild-type mice experienced the normal tolerance to MOP stimulation. These studies suggested that an enhanced release of β -endorphin during neuropathic pain produced stimulation of MOP and subsequent phosphorylation and desensitization, which was observed in wild-type but not in β -endorphin knockout mice (Petraschka *et al.*, 2007; Niikura *et al.*, 2008a,b; Narita *et al.*, 2013). Hence, β -endorphin activity would not be sufficient to modulate the nociceptive manifestations of chronic pain, although it could affect the functionality of opioid receptors.

Penk-deficient mice were generated in C57BL/6 and DBa2 backgrounds with deletions in exon 3 of the *Penk* gene (König *et al.*, 1996; Ragnauth *et al.*, 2001). It needs to be noted that *Penk* deletion suppresses the production not only of enkephalins but also of different peptides coded by the same gene




Figure 3

Use of endogenous opioids knockout mice in chronic pain models. Cold, cold sensitivity; Heat, heat sensitivity; KO: knockout; Mechano, mechanical sensitivity; MIA, monoiodoacetate model; TCA, tricyclic antidepressants. *Only result on affective/cognitive behaviour found in the endogenous opioid knockouts subjected to chronic pain models. Black boxes: C57BL/6 background; black-brown boxes: C57BL/6-129S; brown box: 129S.

(peptides B, E and I) and does not fully remove the production of enkephalins, as they are also coded by the *Pdyn* and *Pomc* genes (Höllt, 1986). In spite of this, *Penk* deficit increased supraspinal responses to nociceptive stimulation but did not change reflex responses to heat or mechanical stimuli (Kingery *et al.*, 2001; Gendron *et al.*, 2007; Chen *et al.*, 2008). *Penk* suppression also enhanced aggressiveness and anxiety-like behaviour (König *et al.*, 1996; Ragnauth *et al.*, 2001; Bilkei-Gorzo *et al.*, 2004), although the responses in specific tests may be strain-dependent (Bilkei-Gorzo *et al.*, 2004). These mutants also showed a reduced motivation for food (Hayward *et al.*, 2002). While enkephalin deficits are associated with increased depressive-like behaviour and enhancing enkephalin levels with enkephalinase inhibitors showed anti-depressant effects (Chu Sin Chung and Kieffer, 2013), depressive-like behaviour in *Penk*-deficient mice was normal under basal conditions (Bilkei-Gorzo *et al.*, 2007). Prominent increases of MOP and DOP in brain regions involved in emotional processing could have normalized this phenotype (Brady *et al.*, 1999). However, acute stress provoked exacerbated anxiety and depressive-like behaviour in these mutants, whereas stress-induced analgesia was not modified (Ragnauth *et al.*, 2001; Kung *et al.*, 2010; Parikh *et al.*, 2011). Thus, the anxious phenotype of the *Penk* knockout mice coexisted with increased supraspinal responses to noxious stimulation, but the magnitude of reflexive responses to nociceptive inputs was unaffected under physiological conditions.

Few studies have explored the consequences of *Penk* ablation in chronic pain (Labuz *et al.*, 2016; Walwyn *et al.*, 2016). Heat and mechanical sensitization was normal in models of inflammatory and neuropathic pain (Celik *et al.*, 2016; Walwyn *et al.*, 2016). Conversely, nerve-injured mice receiving T-lymphocytes from *Penk* knockout donors showed decreased anti-allodynic response compared to mice receiving wild-type lymphocytes (Basso *et al.*, 2016), which could be equivalent to the reduced anti-allodynic effect of exogenous peptides in *Penk* knockouts with peripheral neuropathy (Celik *et al.*, 2016). The absence of major modifications in the nociceptive manifestations of chronic inflammatory or neuropathic pain after the genetic suppression of the main precursors of the opioid peptides acting on MOP and DOP is in contrast to the changes on these chronic pain manifestations revealed in MOP and DOP knockouts. These controversial findings have suggested the possible relevance of ligand-independent opioid receptor constitutive activity in the control of nociceptive responses during chronic pain (Corder *et al.*, 2013; Walwyn *et al.*, 2016). Another plausible explanation is that endorphins and enkephalins can bind both MOP and DOP with very slight differences in affinity (Kosterlitz, 1985). Thus, each peptide type may generate similar physiological responses in the absence of the other, and this compensation may be stronger under pathological conditions that could modify their expression. According to the previous data, the aberrant affective behaviour of enkephalin knockouts did not affect nociceptive sensitization, but the emotional-like manifestations of chronic pain have not been evaluated in these mice. Enkephalin suppression may modify the affective consequences of chronic pain without altering the extent of the nociceptive sensitization, but this remains to be explored.

Studies on knockout mice deficient in KOP and their endogenous ligands

KOP knockout mice were generated by deleting exon 1 (Simonin *et al.*, 1998) or 3 (Hough *et al.*, 2000) of the *Oprk1* gene in C57BL/6/129S or C57BL/6 background respectively (Figure 2). These mice showed normal (Simonin *et al.*, 1998; Martin *et al.*, 2003; Xu *et al.*, 2004; Negrete *et al.*, 2016) or slightly enhanced (Martin *et al.*, 2003; Gavériaux-Ruff *et al.*, 2008) baseline sensitivity to mechanical and thermal stimuli. Inflammatory and nociceptive responses were unchanged in the formalin test, whereas visceral pain was increased in the writhing test (Simonin *et al.*, 1998; Martin *et al.*, 2003). In spite of the involvement of KOP in dysphoria, anxiety and aversive effects of stress (Land *et al.*, 2009), constitutive deletion of the receptor had no consequences on anxiety- and depressive-like behaviour (Simonin *et al.*, 1998; Filliol *et al.*, 2000), and spatial memory was unaffected (Jamot *et al.*, 2003).

Removal of KOP favours a phenotype prone to nociceptive sensitization in chronic pain. These mutants showed increased heat sensitization after streptozotocin-induced diabetic neuropathy (Rutten *et al.*, 2014) and enhanced heat and mechanical sensitivity as well as a contralateral mirror-image sensitization after PSNL (Xu *et al.*, 2004). Surprisingly, the same authors showed that these knockouts displayed reduced spinal cord astrocytosis after PSNL (Xu *et al.*, 2007). Increased and contralateral sensitization was also reported in the CFA model of inflammatory pain (Schepers *et al.*, 2008), although another study did not show abnormal sensitivity in the same CFA model probably due to the high baseline sensitivity of the mice used (Gavériaux-Ruff *et al.*, 2008). The model of monoiodoacetate-induced osteoarthritis pain also revealed enhanced mechanical sensitivity in these mutants, although anxiety-like behaviour and cognitive impairment associated to these chronic pain manifestations were attenuated (Negrete *et al.*, 2016). Another model of osteoarthritis showed enhanced joint damage in KOR knockouts (Wu *et al.*, 2017), and increased formation of cancellous bone was observed in these mice (Baldock *et al.*, 2012), suggesting that the effects of KOP deletion on chronic osteoarthritis pain could also be local. However, no histological modifications were found on the articular cartilage in KOP knockouts after monoiodoacetate (Negrete *et al.*, 2016). Taking all the results together, KOP seem to have protective effects against nociceptive sensitization and detrimental effects promoting anxiety-like behaviour and cognitive impairment associated with chronic pain.

Pdyn-deficient mice were obtained by targeted disruption of exons 3 and 4 of the *Pdyn* gene in C57BL/6, 129S and BALB/c backgrounds (Sharifi *et al.*, 2001; Zimmer *et al.*, 2001; Loacker *et al.*, 2007) (Figure 3). *Pdyn* gene disruption results in the ablation of **dynorphin**, several enkephalin peptides and the **α -neoendorphin**. Baseline sensitivity to heat and mechanical stimuli were not modified (Wang *et al.*, 2001; Zimmer *et al.*, 2001; McLaughlin *et al.*, 2003; Parikh *et al.*, 2011), although certain experimental conditions have revealed increased sensitivity to mechanical (Walwyn *et al.*, 2016) and heat stimuli (Wang *et al.*, 2001). Furthermore, removal of the *Pdyn* gene decreased anxiety (Wittmann *et al.*, 2009; Kastenberger *et al.*, 2012), whereas depressive-like

behaviour was generally unaffected, although punctual increases were also reported (Kastenberger *et al.*, 2012). Dynorphin deficits suppressed stress-induced analgesia after forced swimming or social defeat in the hot tail withdrawal test (McLaughlin *et al.*, 2003), whereas the hot plate responses were preserved after different forced swimming paradigms (Parikh *et al.*, 2011).

Pdyn knockouts have been evaluated in different chronic pain models. Acute inflammatory pain was increased in the late phase of the formalin test (Wang *et al.*, 2001). In contrast, mechanical hypersensitivity after chronic sciatic nerve constriction (Labuz *et al.*, 2016) and mechanical and heat hypersensitivity after spinal nerve ligation or PSNL were decreased (Wang *et al.*, 2001; Xu *et al.*, 2004). In agreement, the latter study showed a reduction in KOP phosphorylation in the spinal cord accompanied by reduced astrocytosis in *Pdyn* knockouts after PSNL, suggesting a pronociceptive role of *Pdyn* gene products (Xu *et al.*, 2007). Likewise, nerve-injured dynorphin-deficient mice did not develop tolerance to a KOP agonist, unlike wild-type mice (Xu *et al.*, 2004). *Pdyn* knockouts showed enhanced mechanical nociception after CFA, although this was attributed to an increased baseline sensitivity (Walwyn *et al.*, 2016). Another study failed to show differences in pain sensitization after CFA (Gendron *et al.*, 2007). Conversely, mice lacking dynorphin showed increased sensitization to mechanical stimuli and developed less anxiety-like behaviour during osteoarthritis pain induced by monoiodoacetate (Negrete *et al.*, 2016). Thus, dynorphins seem to play a complex role during chronic pain, dependent on the pain condition. Indeed, results in *Pdyn* knockouts suggest antinociceptive effects of *Pdyn* gene products in inflammatory pain conditions, whereas neuropathic pain models suggest pronociceptive effects. While *Pdyn* antinociception matches with the pain-limiting effects of the KOP seen in *Oprk1* knockouts, the enhanced pain phenotype in neuropathic conditions diverges from the antinociceptive role of the KOP observed in these models. Thus, dynorphins may facilitate pain sensitization through other opioid or non-opioid receptor/s during neuropathic pain. Additionally, *Pdyn* gene products could participate in the affective component of chronic pain, promoting anxiety-like behaviour.

Studies on knockout mice deficient in NOP and their endogenous ligand

Constitutive NOP knockout mice were generated by deletion of exon 2 and 3 (Clarke *et al.*, 2001) and by deletion of exon 1 of the *Oprl1* gene in a mixed C57BL/6-129S background (Nishi *et al.*, 1997) (Figure 2). NOP constitutive deletion did not modify acute thermal and mechanical nociception, and morphine analgesia and withdrawal signs were unaltered suggesting that NOP was not essential in these responses (Nishi *et al.*, 1997; Mamiya *et al.*, 2001). Interestingly, these mutants showed a consistent reduction of tolerance to morphine analgesia, revealing the involvement of NOP in the mechanisms underlying morphine tolerance (Ueda *et al.*, 1997; Chung *et al.*, 2006).

Knockouts deficient for the precursor of N/OFQ were generated by altering exon 2 in a C57BL/6 background (Köster *et al.*, 1999) (Figure 3). As a consequence, these animals were

lacking OFQ, OFQ2 and **nocistatin**. These mutants showed an elevated basal pain threshold in the tail-flick but developed normal stress-induced analgesia and spatial learning performance. The mutants showed impaired adaptation to basal stress suggesting a role of N/OFQ in these responses to stress. In contrast, other authors have revealed an increased sensitivity in the tail-flick test in N/OFQ knockouts (Chen *et al.*, 1999; Mogil and Pasternak, 2001).

The use of both knockout lines has also provided evidence on the participation of the N/OFQ system in other physiological processes, such as locomotion (Marti *et al.*, 2004) and emotional-like responses (Redrobe *et al.*, 2002; Gavioli *et al.*, 2003). More recently, NOP knockout rats have been obtained by means of the premature stop codon using N-ethyl-N-nitrosourea-driven mutagenesis (Homberg *et al.*, 2009). Mutant rats are more sensitive to morphine reward (Rutten *et al.*, 2011) and showed differences in anxiety and mood-related behaviours, locomotion and nociception, mainly in the formalin test (Rizzi *et al.*, 2011).

The role of the N/OFQ system in chronic pain was also studied using NOP and N/OFQ knockout mice (Depner *et al.*, 2003). These mutants showed stronger nociceptive responses in the late phase of the formalin test and increased thermal pain in the zymosan inflammatory model suggesting a protective role of the N/OFQ system during prolonged inflammatory pain. In contrast, NOP deletion prevented the appearance of posttherapeutic allodynia, although it did not affect the development of skin lesions and allodynia during the presence of these lesions (Sasaki *et al.*, 2008). Therefore, the N/OFQ system may be involved in the transition from herpetic to posttherapeutic allodynia.

NOP-deficient mice were also used to study the interdependency between NOP and the different opioid receptors in streptozotocin-induced diabetic polyneuropathy (Rutten *et al.*, 2014). Selective agonists for each opioid receptor induced smaller analgesic responses in the hot plate in MOP, DOP, KOP and NOP knockouts compared with wild-type littermates. No evidence was shown of the interdependency of NOP and MOP suggesting the interest of its concurrent activation in chronic pain. In contrast, the antinociceptive (Lutfy *et al.*, 2003), motor stimulatory and rewarding actions (Marquez *et al.*, 2008) of buprenorphine were enhanced in NOP knockouts. The interaction between NOP and opioid receptors may work at circuit level as they share common signalling pathways in different anatomical regions, such as the spinal cord, PAG and RVM (Günther *et al.*, 2018). The effect of mixed NOP/MOP agonists inhibiting tolerance and dependence compared with pure MOP agonists may be due to a chronic desensitization of NOP signalling in reward and tolerance circuits (Lutfy *et al.*, 2001), as similar results were seen after a co-treatment of MOR receptor agonists with NOP antagonists (Chung *et al.*, 2006).

NOP-mediated effects on pain may be more complex than those from other opioid receptors. Its activation is followed either by pronociceptive or antinociceptive effects, depending on the administration route and pain modalities in rodents (Schröder *et al.*, 2014). Activation of spinal NOP in models of chronic pain caused potent antihyperalgesic and antiallodynic effects that can be explained at least in part by an up-regulation of those receptors in the spinal cord

(Kiguchi *et al.*, 2016). However, the supraspinal actions of NOP activation gave conflicting results depending on the model. While it seemed to elicit pronociceptive effects in inflammatory pain models, antinociceptive effects were observed in neuropathic pain models, whereas antagonists produced similar attenuation in both types of pain (Kiguchi *et al.*, 2016). Additionally, preproN/OFQ and NOP receptor knockout mice showed increased inflammatory hyperalgesia in the formalin assay, but not in an acute pain assay (Depner *et al.*, 2003). These results were similar to those obtained in NOP receptor knockout rats (Rizzi *et al.*, 2011). In summary, these studies indicate the possibility that the NOP system behaved differently in the different pain models and that its plasticity may participate in some degree in the nociceptive responses induced by chronic pain models (Toll *et al.*, 2016). Heterogeneous outcomes may be explained by various levels of spinal versus supraspinal participation of the NOP/NOFQ system under different pain states (Kiguchi *et al.*, 2016).

Clinical interest of the multitarget approach

Findings obtained with these N/OFQ system knockouts and results of pharmacological studies have suggested a new therapeutic approach based on the development of opioid compounds targeting several opioid receptors, in contrast to the traditional high selectivity of agonists (Bird and Lambert, 2015). Early pharmacological studies already demonstrated beneficial effects of co-administering several drugs acting in different opioid receptors. Thus, a reduction in the development of morphine tolerance was revealed when concomitantly administered with the DOP antagonist **naltrindole** (Abdelhamid *et al.*, 1991). Similarly, morphine tolerance did not appear in *Penk* knockouts (Nitsche *et al.*, 2002), and several studies have revealed the blockade of morphine tolerance in DOP and NOP knockouts (Ueda *et al.*, 1997; Zhu *et al.*, 1999; Chung *et al.*, 2006). In agreement, various mixed MOP/NOP ligands have demonstrated potent analgesic effects in several rodent models together with attenuation in the development of tolerance or physical dependence (Sukhtankar *et al.*, 2013; Sobczak *et al.*, 2014; Zielińska *et al.*, 2015), suggesting the potential interest of using drugs simultaneously targeting NOP and MOP (Blair Journigan *et al.*, 2014). Recently, Toll *et al.* (2016) have reviewed the influence of the activation or blockade of N/OFQ system on the development of opioid tolerance. Morphine tolerance is significantly reduced in NOP or ppN/N/OFQ KO mice (Ueda *et al.*, 1997; Chung *et al.*, 2006). Additionally, N/OFQ antibody partly reversed the tolerance associated with chronic morphine administration (Tian and Han, 2000). These results agree with the report that the co-administration of **J-113397**, an antagonist of the NOP, blocks tolerance development in mice (Ueda *et al.*, 1997; Chung *et al.*, 2006). The application of such antagonists in the ventrolateral PAG blocked the analgesic action of morphine (Scoto *et al.*, 2010) and **DAMGO** (Parenti and Scoto, 2010). Although i.c.v. injection of N/OFQ after a daily systemic administration of morphine blocked morphine tolerance (Lufty *et al.*, 2001), NOP antagonists also blocked the expression of tolerance to a

daily injection of morphine (Zaratin *et al.*, 2004; Chung *et al.*, 2006). Toll *et al.* (2016) concluded that chronic morphine leads to up-regulation of the brain NOP system, which attenuates morphine analgesia and can be blocked with a NOP antagonist. They suggested the need of new studies to better understand the involvement of the NOP system, given the conflicting results with agonists and antagonists (Toll *et al.*, 2016). In this sense, a novel full MOP agonist and NOP partial agonist displaying subnanomolar affinity for both receptors, **cebranopadol**, has been extensively studied at preclinical level (Bird and Lambert, 2015; Sałat *et al.*, 2015). This drug has long-term analgesic effects in acute and chronic pain models, and its side effects are less severe than those of standard opioid drugs. Indeed, motor coordination and respiratory function remains unaltered at high doses, and tolerance is delayed compared with morphine (Sukhtankar *et al.*, 2013; Linz *et al.*, 2014; Schunk *et al.*, 2014; Raffa *et al.*, 2017). According to ClinicalTrials.gov (National Institutes of Health, 2017), seven Phase II clinical trials have been completed with cebranopadol. These studies analysed its analgesic effects in painful diabetic polyneuropathy, postoperative pain, severe chronic low back pain and chronic pain due to osteoarthritis of the knee. Two Phase III clinical trials were also carried out in cancer pain. Some of these clinical studies finished several years ago, but the results have not been yet published. This information would be necessary to understand the real clinical interest of targeting, with the same ligand, MOP and NOP for the treatment of acute or chronic pain in patients.

Current and future directions

Novel genetic approaches have been recently developed to manipulate specific neuronal populations in live animals as well as new techniques that facilitate the simplicity of making gene mutations in rodents. The application of these new techniques can provide important advances in the near future for understanding many neurophysiological processes. The novel genetic techniques most commonly employed to selectively manipulate specific neuronal populations are optogenetics, using channels activated by light, and chemogenetics, using engineered G-protein coupled receptors activated by otherwise inert drugs (Whissell *et al.*, 2016).

Optogenetic approaches have been applied to manipulate specific neuronal populations and have been recently used to study specific components of the pain circuitry (Copits *et al.*, 2016). In these approaches, light-sensitive proteins, called **opsins**, are expressed in genetically defined neuronal populations. The majority of these opsins are light-gated ion channels and pumps isolated from diverse microorganisms (Fenno *et al.*, 2011). Excitatory opsins are cation-selective and gate inward photocurrents that depolarize neurons, whereas inhibitory opsins are most frequently pumps that mediate **chloride** influx or proton efflux to silence neuronal firing (Copits *et al.*, 2016). These optical approaches have also been developed for manipulating intracellular signalling cascades associated with G-protein-coupled receptors, including MOP (Siuda *et al.*, 2015). Opsins are delivered into the nervous system through viral vectors or transgenesis (Copits *et al.*, 2016). Cre-dependent adeno-associated viruses

containing opsin genes are usually injected into transgenic mice where Cre-recombinase expression is restricted to genetically defined cell types. On the other hand, crossing Cre driver transgenic mice with genetically encoded opsin mouse lines can enable specific photo-manipulation of defined neuronal populations (Wang *et al.*, 2016). These manipulations have already been employed to clarify the neuronal pathways involved in chronic pain control. Thus, optogenetic manipulation of the neuronal activity in the medial prefrontal cortex (Ji and Neugebauer, 2012; Zhang *et al.*, 2015) and basolateral amygdala (Kiritoshi *et al.*, 2016) has identified the specific contribution of these circuits in the sensory and emotional components of chronic pain. Optogenetic stimulation of cortical projections to the nucleus accumbens decreased chronic pain manifestations (Sugimura *et al.*, 2016), whereas optogenetic stimulation of the central amygdala induced visceral pain (Crock *et al.*, 2012). These approaches have also allowed the dissection of specific roles of serotonergic neurons of the rostral ventral medulla (Cai *et al.*, 2014) and subpopulations of noradrenergic neurons in the locus coeruleus (Hickey *et al.*, 2014) in pain control. An optogenetic approach has also been used to dissect the specific contribution of opioid and GABA receptors in the pre-synaptic modulation of the nociceptive information transmitted to spinal neurons (Honsek *et al.*, 2015). Interestingly, MOP pre-synaptic activation mainly inhibited C-fibres innervating lamina I spinal cord neurons, whereas activation of pre-synaptic DOP did not modify these responses. In a similar location (spinal cord laminae I/II), another study found that a MOP agonist inhibited excitatory postsynaptic currents elicited by TRPV1 nociceptors optogenetically activated. The inhibition disappeared after removal of the MOP agonist and was followed

by long-term potentiation indicative of excitatory opioid effects. Because these effects were absent in conditional knockouts lacking MOP in TRPV1 nociceptors and correlated with suppression of opioid-induced hyperalgesia in these mice, a fundamental role of presynaptic MOP could be defined in these processes (Corder *et al.*, 2017). Hence, these interesting approaches are already helping to understand how opioid receptors function in specific locations of the nociceptive pathways.

The chemogenetic approach most widely used in neuroscience to selectively manipulate specific brain circuits by modifying the activity of G-protein-coupled receptors is the designed receptor exclusively activated by designed drugs (DREADD) technique (Whissell *et al.*, 2016). The engineered designer receptor must first be selectively expressed in the targeted neuronal population. DREADDs are usually modified muscarinic receptors coupled to an inhibitory (G_i) or excitatory (G_q, G_s) signalling cascade with low affinity for endogenous ligands and activated by synthetic compounds, such as clozapine N-oxide (CNO), an inert and orally available drug. The genes encoding these designer receptors are usually introduced in cells by Cre-dependent adeno-associated viruses restricting DREADD expression to cells that selectively express Cre. The administration of CNO will decrease or increase the activity of this specific neuronal circuit depending on the signalling cascade coupled to the designer receptor expressed (Whissell *et al.*, 2016). These techniques have been used to clarify the specific involvement of different spinal cord neuronal populations in itch (Bourane *et al.*, 2015), acute (Peirs *et al.*, 2015; Saloman *et al.*, 2016) and chronic pain (Peirs *et al.*, 2015), and supraspinal circuits of visceral pain (Jurik *et al.*, 2015). However, none of these




Figure 4

Effects of opioid receptors activating (ON) or inhibiting (OFF) chronic inflammatory or neuropathic pain manifestations, according to knockout studies. Endogenous opioids bind to opioid receptors with different affinities. Arrow thickness indicates relative affinity for the receptor. β -end, β -endorphin; Dyn, dynorphins; Enk, enkephalins; NMDAR, N-methyl-D-aspartate receptor. Dynorphins were described to have high affinity for KOP and low for MOP and NDMA receptors (non-opioid receptor). Pink arrow in MOP indicates possible constitutive activity independent of ligand activation. Effects of MOP are described according to exon 2/2–3 knockout studies. Additional studies are needed to characterize affective/cognitive behaviour associated with chronic pain in these knockouts.

studies has yet examined the function of the endogenous opioid system in chronic pain conditions.

The use of clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology is revolutionizing genetics in many organisms including laboratory mice. The CRISPR system is a versatile antiviral defence mechanism that provides immunity for a host bacterium against extra-chromosomal genetic material (Mojica and Montoliu, 2016). After the acquisition of foreign DNA by the bacterium, this system involves the synthesis and maturation of CRISPR RNA followed by the formation of RNA-Cas nuclease protein complexes that will selectively recognize and destroy the targeted foreign DNA by Cas nuclease cleavage. The CRISPR/Cas9 is a versatile system able to recognize virtually any sequence in the genome, including the mammalian genome, and introduce a controlled break in the DNA (Singh *et al.*, 2015). This novel technology has opened a plethora of possibilities for precise genome editing in mice allowing nearly any possible change mimicking human coding variants to be introduced in the mouse genome. An important progress has been already made in targeting specificity, simplicity of making gene-editing mice and bioinformatics design (Pulido-Quetglas *et al.*, 2017). Although improvements may still be needed to increase precise editing efficiency and decrease mosaicism (Singh *et al.*, 2015), this technology provides entirely new tools extremely useful to conduct genetic mouse research faster and better. A recent study on a model of intervertebral disc degeneration (Stover *et al.*, 2017) detected specific changes in the activity of dorsal root ganglion neurons, associated with the A kinase anchor protein AKAP150, a protein that recruits the cAMP-dependent protein kinase (PKA) to the dendrites. These authors utilized CRISPR epigenome editing to modulate endogenous expression of AKAP150 and could erase the pathological neuronal activity while preserving normal activity. This highlights the potential use of CRISPR as a pain neuromodulatory strategy. Due to the close relationship of PKA with the processes associated to opioid receptor stimulation, it would be interesting to evaluate opioid function in these experimental conditions. However, the possibilities offered by CRISPR/Cas9 are immense.

All these novel genetic techniques will certainly provide in the near future important advances to our understanding of the neurobiological mechanisms underlying chronic pain and the specific involvement of the different components of the endogenous opioid system in these pathophysiological processes. Optogenetic or chemogenetic control of MOP expressed in genetically defined circuits could clarify their role in the nociceptive and affective manifestations of chronic pain, whereas an optimized genomic editing could avoid compensatory changes and disrupt the expression of opioid peptides with common receptor affinities to clarify their participation in chronic pain phenotypes.

Concluding remarks

Studies using knockout mice have allowed the identification the crucial role of DOP and KOP in chronic inflammatory and neuropathic pain (Figure 4). However, these approaches have not yet clarified the precise role of MOP in the

development of different chronic pain conditions. Data suggest that stimulation of peripheral and central MOP could exert antinociceptive effects during certain chronic inflammatory pain conditions, but it may be counterproductive during pathological neuropathic pain or after repeated opioid treatments. The clarification of the role of the different MOP splice variants in the development of chronic pain may, as well, open new therapeutic avenues. MOP is the main opioid receptor for acute nociceptive control and the elucidation of its specific roles in chronic pain merits further studies. In contrast to these findings in opioid receptor knockouts, the suppression of the main precursors of the opioid peptides acting on MOP and DOP had no major consequences on chronic pain manifestations. This suggests either a possible role of ligand-independent opioid receptor constitutive activity or a redundancy in the opioid system in which the presence of one opioid peptide can compensate for the absence of other with similar receptor affinity. Interestingly, β -endorphin activity was revealed necessary for the development of morphine tolerance, whereas the effects of dynorphins could differ depending on the chronic pain condition. Another important open question is to understand the possible influence of the emotional changes revealed in these knockouts in chronic pain manifestations, as the affective aspects of chronic pain may be independent of strictly nociceptive manifestations. The N/OFQ system also seems to play an important role in specific chronic pain conditions and seems essential for the development of opioid analgesic tolerance. These findings have opened a new possible therapeutic approach consisting of mixed MOP/NOP ligands that showed beneficial effects in preclinical studies, but the results of the already completed clinical trials have not been yet published. The novel genetic tools now available to manipulate specific neuronal populations are already providing answers on the functioning of the opioid system, and quick and precise genome editing in mice will facilitate the elucidation of most of these still open questions in the pathophysiology and treatment of chronic pain.

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al.*, 2017), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al.*, 2017a,b).

Acknowledgments

This work was supported by the European Commission, FP7 (#HEALTH-F2-2013-602891), the Spanish *Ministerio de Economía y Competitividad*-MINECO (#SAF2014-59648-P/FEDER) and *Instituto de Salud Carlos III*, RETICS-RTA (#RD12/0028/0023/FEDER), and the *Generalitat de Catalunya*, AGAUR (#2014-SGR-1547). We also acknowledge the financial support of the AGAUR (ICREA Acadèmia Award 2015) to R.M.

Conflict of interest

The authors declare no conflicts of interest.

References

- Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE (1991). Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. *J Pharmacol Exp Ther* 258: 299–303.
- Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA *et al.* (2017a). The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. *Br J Pharmacol* 174: S17–S129.
- Alexander SPH, Striessnig J, Kelly E, Marrion NV, Peters JA, Faccenda E *et al.* (2017b). The Concise Guide to PHARMACOLOGY 2017/18: Voltage-gated ion channels. *Br J Pharmacol* 174: S160–S194.
- Baldock PA, Driessler F, Lin S, Wong IPL, Shi Y, Yulyaningsih E *et al.* (2012). The endogenous opioid dynorphin is required for normal bone homeostasis in mice. *Neuropeptides* 46: 383–394.
- Basso L, Boué J, Mahiddine K, Blanpied C, Robiou-du-Pont S, Vergnolle N *et al.* (2016). Endogenous analgesia mediated by CD4+ T lymphocytes is dependent on enkephalins in mice. *J Neuroinflammation* 13: 132.
- Becker JAJ, Clesse D, Spiegelhalter C, Schwab Y, Le Merrer J, Kieffer BL (2014). Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity. *Neuropsychopharmacology* 39: 2049–2060.
- Benbouzid M, Gavériaux-Ruff C, Yalcin I, Waltisperger E, Tessier L-H, Muller A *et al.* (2008). Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. *Biol Psychiatry* 63: 633–636.
- Bilkei-Gorzo A, Michel K, Noble F, Roques BP, Zimmer A (2007). Preproenkephalin knockout mice show no depression-related phenotype. *Neuropsychopharmacology* 32: 2330–2337.
- Bilkei-Gorzo A, Racz I, Michel K, Zimmer A, Klingmüller D, Zimmer A (2004). Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds. *Psychopharmacology (Berl)* 176: 343–352.
- Bird MF, Lambert DG (2015). Simultaneous targeting of multiple opioid receptor types. *Curr Opin Support Palliat Care* 9: 98–102.
- Blair Journigan V, Polgar WE, Khroyan TV, Zaveri NT (2014). Designing bifunctional NOP receptor–mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II. *Bioorg Med Chem* 22: 2508–2516.
- Bodnar RJ (2017). Endogenous opiates and behavior: 2015. *Peptides* 88: 126–188.
- Bohren Y, Karavelic D, Tessier L-H, Yalcin I, Gavériaux-Ruff C, Kieffer BL *et al.* (2010). Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia. *Eur J Pain* 14: 700–704.
- Bourane S, Duan B, Koch SC, Dalet A, Britz O, Garcia-Campmany L *et al.* (2015). Gate control of mechanical itch by a subpopulation of spinal cord interneurons. *Science* 350: 550–554.
- Brady LS, Herkenham M, Rothman RB, Partilla JS, König M, Zimmer AM *et al.* (1999). Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. *Brain Res Mol Brain Res* 68: 193–197.
- Bushnell MC, Ceko M, Low LA (2013). Cognitive and emotional control of pain and its disruption in chronic pain. *Nat Rev Neurosci* 14: 502–511.
- Cai Y-Q, Wang W, Hou Y-Y, Pan ZZ (2014). Optogenetic activation of brainstem serotonergic neurons induces persistent pain sensitization. *Mol Pain* 10: 70.
- Celik MÖ, Labuz D, Henning K, Busch-Dienstfertig M, Gavériaux-Ruff C, Kieffer BL *et al.* (2016). Leukocyte opioid receptors mediate analgesia via Ca(2+)-regulated release of opioid peptides. *Brain Behav Immun* 57: 227–242.
- Chen TC, Cheng YY, Sun WZ, Shyu BC (2008). Differential regulation of morphine antinociceptive effects by endogenous enkephalinergic system in the forebrain of mice. *Mol Pain* 4: 1741–1744.
- Chen Z, Inoue M, Hopkins E, Pellegrino MJ, Novakowki R, Mogil JS *et al.* (1999). Nociceptin/OFQ gene knock-out reveals an antinociceptive role for the nociceptin/OFQ in the mouse. *Soc Neurosci Abstr* 25: 1472.
- Chu Sin Chung P, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E *et al.* (2015). Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. *Behav Brain Res* 278: 429–434.
- Chu Sin Chung P, Kieffer BL (2013). Delta opioid receptors in brain function and diseases. *Pharmacol Ther* 140: 112–120.
- Chung S, Pohl S, Zeng J, Civelli O, Reinscheid RK (2006). Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. *J Pharmacol Exp Ther* 318: 262–267.
- Clarke S, Chen Z, Hsu MS, Pintar J, Hill R, Kitchen I (2001). Quantitative autoradiographic mapping of the ORL1, μ -, δ - and κ -receptors in the brains of knockout mice lacking the ORL1 receptor gene. *Brain Res* 906: 13–24.
- Copits BA, Pullen MY, Gereau RW (2016). Spotlight on pain: optogenetic approaches for interrogating somatosensory circuits. *Pain* 157: 2424–2433.
- Corder G, Doolen S, Donahue RR, Winter MK, Jutras BL, He Y *et al.* (2013). Constitutive μ -opioid receptor activity leads to long-term endogenous analgesia and dependence. *Science* 341: 1394–1399.
- Corder G, Tawfik VL, Wang D, Sypek EI, Low SA, Dickinson JR *et al.* (2017). Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. *Nat Med* 23: 164–173.
- Crock LW, Kolber BJ, Morgan CD, Sadler KE, Vogt SK, Bruchas MR *et al.* (2012). Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain. *J Neurosci* 32: 14217–14226.
- Depner UB, Reinscheid RK, Takeshima H, Brune K, Zeilhofer HU (2003). Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor. *Eur J Neurosci* 17: 2381–2387.
- Dierich A, Kieffer BL (2004). Knockout mouse models in pain research. *Methods Mol Med* 99: 269–299.
- Fell GL, Robinson KC, Mao J, Woolf CJ, Fisher DE (2014). Skin β -endorphin mediates addiction to UV light. *Cell* 157: 1527–1534.
- Fenko L, Yizhar O, Deisseroth K (2011). The development and application of optogenetics. *Annu Rev Neurosci* 34: 389–412.
- Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F *et al.* (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. *Nat Genet* 25: 195–200.
- Fuchs PN, Roza C, Sora I, Uhl G, Raja SN (1999). Characterization of mechanical withdrawal responses and effects of mu-, delta- and

- kappa-opioid agonists in normal and mu opioid receptor knockout mice. *Brain Res* 821: 480–486.
- Gavériaux-Ruff C (2013). Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants. *Curr Pharm Des* 19: 7373–7381.
- Gavériaux-Ruff C, Karchewski LA, Hever X, Matifas A, Kieffer BL (2008). Inflammatory pain is enhanced in delta opioid receptor-knockout mice. *Eur J Neurosci* 27: 2558–2567.
- Gavériaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, Matifas A *et al.* (2011). Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. *Pain* 152: 1238–1248.
- Gavioli EC, Marzola G, Guerrini R, Bertorelli R, Zucchini S, De Lima TCM *et al.* (2003). Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressantlike effects: pharmacological and genetic evidences from the mouse forced swimming test. *Eur J Neurosci* 17: 1987–1990.
- Gendron L, Pintar JE, Chavkin C (2007). Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. *Neuroscience* 150: 807–817.
- Günther T, Dasgupta P, Mann A, Miess E, Kiewer A, Fritzwanker S *et al.* (2018). Targeting multiple opioid receptors – improved analgesics with reduced side effects? *Br J Pharmacol*. 175: 2857–2868.
- Hayward MD, Pintar JE, Low MJ (2002). Selective reward deficit in mice lacking beta-endorphin and enkephalin. *J Neurosci* 22: 8251–8258.
- Henriksen G, Willoch F (2008). Imaging of opioid receptors in the central nervous system. *Brain* 131: 1171–1196.
- Hickey L, Li Y, Fyson SJ, Watson TC, Perrins R, Hewinson J *et al.* (2014). Optoactivation of locus ceruleus neurons evokes bidirectional changes in thermal nociception in rats. *J Neurosci* 34: 4148–4160.
- Höllt V (1986). Opioid peptide processing and receptor selectivity. *Annu Rev Pharmacol Toxicol* 26: 59–77.
- Homberg JR, Mul JD, de Wit E, Cuppen E (2009). Complete knockout of the nociceptin/orphanin FQ receptor in the rat does not induce compensatory changes in mu, delta and kappa opioid receptors. *Neuroscience* 163: 308–315.
- Honsek SD, Seal RP, Sandkühler J (2015). Presynaptic inhibition of optogenetically identified VGLUT3+ sensory fibres by opioids and baclofen. *Pain* 156: 243–251.
- Hough LB, Nalwalk JW, Chen Y, Schuller A, Zhu Y, Zhang J *et al.* (2000). Impropgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. *Brain Res* 880: 102–108.
- Ide S, Minami M, Ishihara K, Uhl GR, Satoh M, Sora I *et al.* (2008). Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in mu-opioid receptor knockout mice. *Neuropharmacology* 54: 1182–1188.
- Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K (2006). Mu opioid receptor-dependent and independent components in effects of tramadol. *Neuropharmacology* 51: 651–658.
- Jamot L, Matthes HWD, Simonin F, Kieffer BL, Roder JC (2003). Differential involvement of the mu and kappa opioid receptors in spatial learning. *Genes Brain Behav* 2: 80–92.
- Ji G, Neugebauer V (2012). Modulation of medial prefrontal cortical activity using *in vivo* recordings and optogenetics. *Mol Brain* 5: 36.
- Jurik A, Auffenberg E, Klein S, Deussing JM, Schmid RM, Wotjak CT *et al.* (2015). Roles of prefrontal cortex and paraventricular thalamus in affective and mechanical components of visceral nociception. *Pain* 156: 2479–2491.
- Kastenberger I, Lutsch C, Herzog H, Schwarzer C (2012). Influence of sex and genetic background on anxiety-related and stress-induced behaviour of prodynorphin-deficient mice. *PLoS One* 7: e34251.
- Kieffer BL, Evans CJ (2009). Opioid receptors: from binding sites to visible molecules *in vivo*. *Neuropharmacology* 56: 205–212.
- Kiguchi N, Ding H, Ko MC (2016). Central N/OFQ-NOP receptor system in pain modulation. *Adv Pharmacol* 75: 217–243.
- Kingery WS, Sawamura S, Agashe GS, Davies MF, Clark JD, Zimmer A (2001). Enkephalin release and opioid receptor activation does not mediate the antinociceptive or sedative/hypnotic effects of nitrous oxide. *Eur J Pharmacol* 427: 27–35.
- Kiritoshi T, Ji G, Neugebauer V (2016). Rescue of impaired mGluR5-driven endocannabinoid signaling restores prefrontal cortical output to inhibit pain in arthritic rats. *J Neurosci* 36: 837–850.
- Kögel B, De Vry J, Tzschentke TM, Christoph T (2011). The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (mu-opioid receptor) knockout mice. *Neurosci Lett* 491: 104–107.
- König M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ *et al.* (1996). Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. *Nature* 383: 535–538.
- Köster A, Montkowski A, Schulz S, Stübe EM, Knaudt K, Jenck F *et al.* (1999). Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. *Proc Natl Acad Sci U S A* 96: 10444–10449.
- Kosterlitz HW (1985). The Wellcome Foundation lecture, 1982. Opioid peptides and their receptors. *Proc R Soc London Ser B, Biol Sci* 225: 27–40.
- Kung J-C, Chen T-C, Shyu B-C, Hsiao S, Huang A (2010). Anxiety- and depressivelike responses and c-fos activity in preproenkephalin knockout mice: oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder. *J Biomed Sci* 17: 29.
- Labuz D, Celik MÖ, Zimmer A, Machelska H (2016). Distinct roles of exogenous opioid agonists and endogenous opioid peptides in the peripheral control of neuropathy-triggered heat pain. *Sci Rep* 6: 32799.
- Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, Messinger D *et al.* (2009). Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. *Proc Natl Acad Sci U S A* 106: 19168–19173.
- Le Merrer J, Rezaei X, Scherrer G, Becker JAJ, Kieffer BL (2013). Impaired hippocampus-dependent and facilitated striatum-dependent behaviors in mice lacking the delta opioid receptor. *Neuropsychopharmacology* 38: 1050–1059.
- Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M *et al.* (2014). Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. *J Pharmacol Exp Ther* 349: 535–548.
- Loacker S, Sayyah M, Wittmann W, Herzog H, Schwarzer C (2007). Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. *Brain* 130: 1017–1028.
- Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN (1998). mu opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. *Brain Res Mol Brain Res* 54: 321–326.

- Lu Z, Xu J, Rossi GC, Majumdar S, Pasternak GW, Pan YX (2015). Mediation of opioid analgesia by a truncated 6-transmembrane GPCR. *J Clin Invest* 125: 2026–2030.
- Luffy K, Hossain SM, Khaliq I, Maidment NT (2001). Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats. *Br J Pharmacol* 134: 529–534.
- Lutty K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn *Wet al.* (2003). Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. *J Neurosci* 23: 10331–10337.
- Lutz PE, Kieffer BL (2013). Opioid receptors: distinct roles in mood disorders. *Trends Neurosci* 36: 195–206.
- Maldonado R (2016). Opioid receptors and drug-seeking behaviour. In INRC Meeting, (Bath, United Kingdom), p 12.
- Mamiya T, Noda Y, Ren X, Nagai T, Takeshima H, Ukai M *et al.* (2001). Morphine tolerance and dependence in the nociceptin receptor knockout mice. *J Neural Transm* 108: 1349–1361.
- Mansikka H, Zhao C, Sheth RN, Sora I, Uhl G, Raja SN (2004). Nerve injury induces a tonic bilateral mu-opioid receptor-mediated inhibitory effect on mechanical allodynia in mice. *Anesthesiology* 100: 912–921.
- Marquez P, Nguyen AT, Hamid A, Lutty K (2008). The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. *Neuropharmacology* 54: 564–568.
- Marrone GF, Le Rouzic V, Varadi A, Xu J, Rajadhyaksha AM, Majumdar S *et al.* (2017). Genetic dissociation of morphine analgesia from hyperalgesia in mice. *Psychopharmacology (Berl)* 234: 1891–1900.
- Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M *et al.* (2004). Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. *J Neurosci* 24: 6659–6666.
- Martin M, Matifas A, Maldonado R, Kieffer BL (2003). Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. *Eur J Neurosci* 17: 701–708.
- Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I *et al.* (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* 383: 819–823.
- McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. *J Neurosci* 23: 5674–5683.
- Meunier JC (1997). Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. *Eur J Pharmacol* 340: 1–15.
- Mogil JS, Grisel JE, Hayward MD, Bales JR, Rubinstein M, Belknap JK *et al.* (2000). Disparate spinal and supraspinal opioid antinociceptive responses in beta-endorphin-deficient mutant mice. *Neuroscience* 101: 709–717.
- Mogil JS, Pasternak GW (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. *Pharmacol Rev* 53: 381–415.
- Mogil JS, Wilson SG (1997). Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. *Eur J Pain* 1: 293–297.
- Mojica FJM, Montoliu L (2016). On the origin of CRISPR-Cas technology: from prokaryotes to mammals. *Trends Microbiol* 24: 811–820.
- Morozov A, Kellendonk C, Simpson E, Tronche F (2003). Using conditional mutagenesis to study the brain. *Biol Psychiatry* 54: 1125–1133.
- Nadal X, Baños J-E, Kieffer BL, Maldonado R (2006). Neuropathic pain is enhanced in delta-opioid receptor knockout mice. *Eur J Neurosci* 23: 830–834.
- Nadal X, La Porta C, Andreea Bura S, Maldonado R (2013). Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. *Eur J Pharmacol* 716: 142–157.
- Narita M, Imai S, Nakamura A, Ozeki A, Asato M, Rahmadi M *et al.* (2013). Possible involvement of prolonging spinal μ -opioid receptor desensitization in the development of antihyperalgesic tolerance to μ -opioids under a neuropathic pain-like state. *Addict Biol* 18: 614–622.
- National Institutes of Health. ClinicalTrials.gov. Accessed January 16, 2017.
- Negrete R, García Gutiérrez MS, Manzanares J, Maldonado R (2016). Involvement of the dynorphin/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice. *Neuropharmacology* 116: 315–327.
- Niikura K, Narita M, Narita M, Nakamura A, Okutsu D, Ozeki A *et al.* (2008a). Direct evidence for the involvement of endogenous beta-endorphin in the suppression of the morphine-induced rewarding effect under a neuropathic pain-like state. *Neurosci Lett* 435: 257–262.
- Niikura K, Narita M, Okutsu D, Tsurukawa Y, Nanjo K, Kurahashi K *et al.* (2008b). Implication of endogenous beta-endorphin in the inhibition of the morphine-induced rewarding effect by the direct activation of spinal protein kinase C in mice. *Neurosci Lett* 433: 54–58.
- Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi *Tet al.* (1997). Unrestrained nociceptive response and dysregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. *EMBO J* 16: 1858–1864.
- Nitsche JF, Schuller AGP, King MA, Zeng M, Pasternak GW, Pintar JE (2002). Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knockout mice. *J Neurosci* 22: 10906–10913.
- Ossipov MH, Dussor GO, Porreca F (2010). Central modulation of pain. *J Clin Invest* 120: 3779–3787.
- Pan Y-X, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW (2009). Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. *Proc Natl Acad Sci U S A* 106: 4917–4922.
- Parenti C, Scoto GM (2010). The functional antiopioid action of the ventrolateral periaqueductal gray nociceptin/orphanin FQ and nociceptin receptor system underlies DAMGO analgesic tolerance. *Pharmacology* 86: 138–144.
- Parikh D, Hamid A, Friedman TC, Nguyen K, Tseng A, Marquez P *et al.* (2011). Stress-induced analgesia and endogenous opioid peptides: the importance of stress duration. *Eur J Pharmacol* 650: 563–567.
- Pasternak GW, Pan YX (2013). Mu opioids and their receptors: evolution of a concept. *Pharmacol Rev* 65: 1257–1317.
- Peirs C, Williams S-PG, Zhao X, Walsh CE, Gedeon JY, Cagle NE *et al.* (2015). Dorsal horn circuits for persistent mechanical pain. *Neuron* 87: 797–812.
- Petrashka M, Li S, Gilbert TL, Westenbroek RE, Bruchas MR, Schreiber S *et al.* (2007). The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid

- receptors following partial sciatic nerve ligation. *Neuroscience* 146: 1795–1807.
- Polunina AG, Bryun EA (2013). Neuropsychological functions of μ - and δ -opioid systems. *ISRN Addict* 2013: 674534: 1–13.
- Povdin S, Yaksch T, Hook V (2016). The emerging role of spinal dynorphin in chronic pain: a therapeutic perspective. *Annu Rev Pharmacol Toxicol* 56: 511–533.
- Pulido-Quetglas C, Aparicio-Prat E, Arnan C, Polidori T, Hermoso T, Palumbo E *et al.* (2017). Scalable design of paired CRISPR guide RNAs for genomic deletion. *PLoS Comput Biol* 13: e1005341.
- Qiu C, Sora I, Ren K, Uhl G, Dubner R (2000). Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. *Eur J Pharmacol* 387: 163–169.
- Raffa RB, Burdge G, Gambrah J, Kinecki HE, Lin F, Lu B *et al.* (2017). Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. *J Clin Pharm Ther* 42: 8–17.
- Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J *et al.* (2001). Female preproenkephalin-knockout mice display altered emotional responses. *Proc Natl Acad Sci U S A* 98: 1958–1963.
- Redrobe JP, Calo' G, Regoli D, Quirion R (2002). Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. *Naunyn Schmiedeberg Arch Pharmacol* 365: 164–167.
- Reiss D, Ceredig RA, Secher T, Boué J, Barreau F, Dietrich G *et al.* (2016). Mu and delta opioid receptor knockout mice show increased colonic sensitivity. *Eur J Pain* 21: 623–634.
- van Rijn RM, Whistler JL (2009). The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. *Biol Psychiatry* 66: 777–784.
- Rittner HL, Brack A, Stein C (2008). Pain and the immune system. *Br J Anaesth* 101: 40–44.
- Rizzi A, Molinari S, Marti M, Marzola G, Calo' G (2011). Nociceptin/orphanin FQ receptor knockout rats: *in vitro* and *in vivo* studies. *Neuropharmacology* 60: 572–579.
- Rubinstein M, Mogil JS, Japón M, Chan EC, Allen RG, Low MJ (1996). Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. *Proc Natl Acad Sci U S A* 93: 3995–4000.
- Rutten K, De Vry J, Bruckmann W, Tzschentke TM (2011). Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. *Drug Alcohol Depend* 114: 253–256.
- Rutten K, Tzschentke TM, Koch T, Schiene K, Christoph T (2014). Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia. *Eur J Pharmacol* 741: 264–271.
- Sałat K, Jakubowska A, Kulig K (2015). Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors. *Expert Opin Investig Drugs* 24: 837–844.
- Saloman JL, Scheff NN, Snyder LM, Ross SE, Davis BM, Gold MS (2016). Gi-DREADD expression in peripheral nerves produces ligand-dependent analgesia, as well as ligand-independent functional changes in sensory neurons. *J Neurosci* 36: 10769–10781.
- Sanders MJ, Kieffer BL, Fanselow MS (2005). Deletion of the mu opioid receptor results in impaired acquisition of Pavlovian context fear. *Neurobiol Learn Mem* 84: 33–41.
- Sasaki A, Takasaki I, Andoh T, Shiraki K, Takeshima H, Takahata H *et al.* (2008). Nociceptin-receptor deficiency prevents postherpetic pain without effects on acute herpetic pain in mice. *Neuroreport* 19: 83–86.
- Schepers RJ, Mahoney JL, Gehrke BJ, Shippenberg TS (2008). Endogenous kappaopioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation. *Pain* 138: 423–439.
- Schröder W, Lambert DG, Ko MC, Koch T (2014). Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. *Br J Pharmacol* 171: 3777–3800.
- Schuller AG, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ *et al.* (1999). Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. *Nat Neurosci* 2: 151–156.
- Schunk S, Linz K, Frommann S, Hinze C, Oberbörsch S, Sundermann B *et al.* (2014). Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as potent NOP and opioid receptor agonists. *ACS Med Chem Lett* 5: 851–856.
- Scoto GM, Aricò G, Iemolo A, Ronsisvalle G, Parenti C (2010). Selective inhibition of the NOP receptor in the ventrolateral periaqueductal gray attenuates the development and the expression of tolerance to morphine-induced antinociception in rats. *Peptides* 31: 696–700.
- Sharifi N, Diehl N, Yaswen L, Brennan MB, Hochgeschwender U (2001). Generation of dynorphin knockout mice. *Brain Res Mol Brain Res* 86: 70–75.
- Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A *et al.* (1998). Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. *EMBO J* 17: 886–897.
- Singh P, Schimenti JC, Bolcun-Filas E (2015). A mouse geneticist's practical guide to CRISPR applications. *Genetics* 199: 1–15.
- Siuda ER, Copits BA, Schmidt MJ, Baird MA, Al-Hasani R, Planer WJ *et al.* (2015). Spatiotemporal control of opioid signaling and behavior. *Neuron* 86: 923–935.
- Sobczak M, Cami-Kobeci G, Sałaga M, Husbands SM, Fichna J (2014). Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrheapredominant irritable bowel syndrome symptoms. *Eur J Pharmacol* 736: 63–69.
- Sora I, Li XF, Funada M, Kinsey S, Uhl GR (1999). Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488. *Eur J Pharmacol* 366: R3–R5.
- Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM *et al.* (1997). Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. *Proc Natl Acad Sci U S A* 94: 1544–1549.
- Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH *et al.* (2017). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. *Nucl Acids Res* 44: D1054–D1068.
- Stover JD, Farhang N, Berrett KC, Gertz J, Lawrence B, Bowles RD (2017). CRISPR epigenome editing of AKAP150 in DRG neurons abolishes degenerative IVD-induced neuronal activation. *Mol Ther pii: S1525-0016(17)30272-1* 25: 2014–2027.
- Sugimura YK, Takahashi Y, Watabe AM, Kato F (2016). Synaptic and network consequences of monosynaptic nociceptive inputs of

- parabrachial nucleus origin in the central amygdala. *J Neurophysiol* 115: 2721–2739.
- Sukhtankar DD, Zaveri NT, Husbands SM, Ko M-C (2013). Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/ μ -opioid receptor ligands in mouse models of neuropathic and inflammatory pain. *J Pharmacol Exp Ther* 346: 11–22.
- Terenius L (2000). From opiate pharmacology to opioid peptide physiology. *Ups J Med Sci* 105: 1–15.
- Tian JH, Han JS (2000). Functional studies using antibodies against orphanin FQ/nociceptin. *Peptides* 21: 1047–1050.
- Tian M, Broxmeyer HE, Fan Y, Lai Z, Zhang S, Aronica S *et al.* (1997). Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. *J Exp Med* 185: 1517–1522.
- Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT (2016). Nociceptin/Orphanin FQ receptor structure, signalling, ligands, functions, and interactions with opioid system. *Pharmacol Rev* 68: 419–457.
- Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM (2015). Pain and poppies: the good, the bad, and the ugly of opioid analgesics. *J Neurosci* 35: 13879–13888.
- Trigo JM, Zimmer A, Maldonado R (2009). Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. *Neuropharmacology* 56: 1147–1153.
- Ueda H, Yamaguchi T, Tokuyama S, Inoue M, Nishi M, Takeshima H (1997). Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene. *Neurosci Lett* 237: 136–138.
- Walwyn WM, Chen W, Kim H, Minasyan A, Ennes HS, McRoberts JA *et al.* (2016). Sustained suppression of hyperalgesia during latent sensitization by μ -, δ -, and κ -opioid receptors and 2A adrenergic receptors: role of constitutive activity. *J Neurosci* 36: 204–221.
- Wang F, Bélanger E, Paquet M-E, Côté DC, De Koninck Y (2016). Probing pain pathways with light. *Neuroscience* 338: 248–271.
- Wang Z, Gardell LR, Ossipov MH, Vanderah TW, Brennan MB, Hochgeschwender U *et al.* (2001). Pronociceptive actions of dynorphin maintain chronic neuropathic pain. *J Neurosci* 21: 1779–1786.
- Weibel R, Reiss D, Karchewski L, Gardon O, Matifas A, Filliol D *et al.* (2013). Mu opioid Receptors on primary afferent Nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. *PLoS One* 8: e74706.
- Whissell PD, Tohyama S, Martin LJ (2016). The use of DREADDs to deconstruct behavior. *Front Genet* 7: 70.
- Wieskopf JS, Pan YX, Marcovitz J, Tuttle AH, Majumdar S, Pidakala J *et al.* (2014). Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene. *Pain* 55: 2063–2070.
- Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y *et al.* (2014). The biology of nociceptin/orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. *Pharmacol Ther* 141: 283–299.
- Wittmann W, Schunk E, Rosskothien I, Gaburro S, Singewald N, Herzog H *et al.* (2009). Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. *Neuropsychopharmacology* 34: 775–785.
- Woolf CJ (2010). What is this thing called pain? *J Clin Invest* 120: 3742–3744.
- Wu L, Zhang S, Shkhyan R, Lee S, Gullo F, Eliasberg CD *et al.* (2017). Kappa opioid receptor signaling protects cartilage tissue against posttraumatic degeneration. *JCI Insight* 2: e88553.
- Xu M, Bruchas MR, Ippolito DL, Gendron L, Chavkin C (2007). Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by opioid activation of p38 mitogen-activated protein kinase. *J Neurosci* 27: 2570–2581.
- Xu M, Petraschka M, McLaughlin JP, Westenbroek RE, Caron MG, Lefkowitz RJ *et al.* (2004). Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. *J Neurosci* 24: 4576–4584.
- Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P *et al.* (2004). Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (–)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). *J Pharmacol Exp Ther* 308: 454–461.
- Zhang Z, Gadotti VM, Chen L, Souza IA, Stemkowski PL, Zamponi GW (2015). Role of prelimbic GABAergic circuits in sensory and emotional aspects of neuropathic pain. *Cell Rep* 12: 752–759.
- Zhao C-S, Tao Y-X, Tall JM, Donovan DM, Meyer RA, Raja SN (2003). Role of μ -opioid receptors in formalin-induced pain behavior in mice. *Exp Neurol* 184: 839–845.
- Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP *et al.* (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. *Neuron* 24: 243–252.
- Zielińska M, Haddou TB, Cami-Kobeci G, Sałaga M, Jarmuż A, Padysz M *et al.* (2015). Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. *Eur J Pharmacol* 765: 582–590.
- Zimmer A, Valjent E, König M, Zimmer AM, Robledo P, Hahn H *et al.* (2001). Absence of delta –9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. *J Neurosci* 21: 9499–9505.